Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP978609.RApzkT6YIFzx_AUZ_Dpz0zeVOmH2EVjop1PjKdImbgLc0130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP978609.RApzkT6YIFzx_AUZ_Dpz0zeVOmH2EVjop1PjKdImbgLc0130_assertion type Assertion NP978609.RApzkT6YIFzx_AUZ_Dpz0zeVOmH2EVjop1PjKdImbgLc0130_head.
- NP978609.RApzkT6YIFzx_AUZ_Dpz0zeVOmH2EVjop1PjKdImbgLc0130_assertion description "[In each category except for RARS, approximately half of the patients progressed, with a slightly less median time to progression in RAEB-T than for the other subtypes of MDS.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP978609.RApzkT6YIFzx_AUZ_Dpz0zeVOmH2EVjop1PjKdImbgLc0130_provenance.
- NP978609.RApzkT6YIFzx_AUZ_Dpz0zeVOmH2EVjop1PjKdImbgLc0130_assertion evidence source_evidence_literature NP978609.RApzkT6YIFzx_AUZ_Dpz0zeVOmH2EVjop1PjKdImbgLc0130_provenance.
- NP978609.RApzkT6YIFzx_AUZ_Dpz0zeVOmH2EVjop1PjKdImbgLc0130_assertion SIO_000772 11960342 NP978609.RApzkT6YIFzx_AUZ_Dpz0zeVOmH2EVjop1PjKdImbgLc0130_provenance.
- NP978609.RApzkT6YIFzx_AUZ_Dpz0zeVOmH2EVjop1PjKdImbgLc0130_assertion wasDerivedFrom befree-20150227 NP978609.RApzkT6YIFzx_AUZ_Dpz0zeVOmH2EVjop1PjKdImbgLc0130_provenance.
- NP978609.RApzkT6YIFzx_AUZ_Dpz0zeVOmH2EVjop1PjKdImbgLc0130_assertion wasGeneratedBy ECO_0000203 NP978609.RApzkT6YIFzx_AUZ_Dpz0zeVOmH2EVjop1PjKdImbgLc0130_provenance.